Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Summary
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.
Official title: A Randomized, Open-labelled, Three-Arm Trial of Gabapentin Versus Benzonatate Versus Standard of Care for Chronic Cough in Interstitial Lung Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
177
Start Date
2026-10-07
Completion Date
2027-07-31
Last Updated
2026-10-08
Healthy Volunteers
No
Conditions
Interventions
Gabapentin
Gabapentin at starting dose of 100 mg per dose, thrice daily and up titrated by 100 mg per dose every 3 days till 300 mg per dose, thrice daily or maximum tolerated dose
Benzonatate 200 mg
Benzonatate at starting dose of 100 mg per dose thrice daily and up titrated to 200 mg per dose thrice daily after 3 days
Standard of care treatment for ILD
Standard Therapy including immunosuppressive and/or anti-fibrotic agent/s and symptomatic therapy for cough (as needed dextromethorphan lozenges)
Locations (1)
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, India